word count: 239 31 Text word count: 3604 32 Number of figures: 6 33 Number of tables: 1 34 2 Number of references: 37 35 36 Key points: 37
Introduction 63
Hematopoietic stem cells (HSCs) in the bone marrow give rise to all blood cells, 64 including mast cells. Differentiating HSCs progress through a number of intermediate 65 progenitors with multilineage-forming capacity before commitment to the mast cell 66 lineage. 1, 2 The binding of stem cell factor (SCF) to its receptor, KIT, promotes the 67 maturation and proliferation of mast cells. [3] [4] [5] [6] It is therefore not surprising that 68 mutations in the KIT gene coincide with the mast cell-driven disease systemic 69 mastocytosis (SM). 7 70 71 SM is a hematologic neoplasm in which infiltrates of neoplastic mast cells occur in 72 various tissues. 8, 9 The majority of SM patients carry a mutation in KIT, most 73 commonly affecting codon 816. 10 The KIT D816V mutation makes receptor signaling 74 constitutively active, independent of binding to its ligand SCF. The detection of KIT 75 D816V in either bone marrow or peripheral blood samples is one of the criteria for the 76 clinical diagnosis of SM using a standardized qPCR assay. 11 When the KIT D816V 77 mutation is present in mast cells, it may also be detected in mature bone marrow or 78 peripheral blood cells, such as basophils, eosinophils, neutrophils, and B and T 79 lymphocytes, which depends on the patient. 12-17 Furthermore, the precursors of 80 erythroid and myeloid cells as well as CD34 + progenitors may carry the KIT D816V 81 mutation. 12, 18, 19 Taken together, these findings suggest that the mutation may arise in 82 early hematopoietic stem and progenitor cells (HSPCs), rather than in a lineage-83 restricted precursor. 84
85
The CD34 + cell compartment is highly heterogeneous, spanning HSCs to late lineage-86 committed progenitors. In the present study, we delineated the cellular origin of the 87 5 KIT D816V mutation in single bone marrow cells in SM by combining FACS index 88 sorting of CD34 + HSPCs with a multiplex qPCR assay. The data revealed that the 89 D816V mutation in KIT arises in early HSPCs. The mutation burden is low but 90 variable in multipotent and lineage-restricted progenitor populations and increases in 91 mature mast cells. Furthermore, the present study provides more insight into 92 hematopoiesis in SM subjects and reveals a novel marker for aberrant mast cells. 93 Table S1 shows the patient characteristics. For 107 analytic purposes, ASM and SM-AHN patients were combined in an advanced SM 108 group (AdvSM). The controls (Ctrl) included patients with cutaneous mastocytosis 109 (CM, n = 2) and subjects without SM (n = 7). All samples were processed on the day 110 of collection. Red blood cells were lysed with PharmLyse buffer (BD Biosciences, 111 7 software version 8 (BD Biosciences). Flow cytometry data analysis was performed 137 using FlowJo software version 10 (TreeStar, Ashland, OR). 138
139
Cell culture and colony-forming assays 140
Colony-forming potential was evaluated by plating 500 cells in 35 x 10 mm tissue 141 culture dishes (Thermo Fisher Scientific) in duplicate. The cells were cultured in 142
Methocult H4434 (STEMCELL Technologies Inc., Vancouver, Canada). Colonies 143 were counted after 12-13 days, distinguishing erythroid, granulocyte/monocyte, and 144 mixed colonies following the manufacturer's recommendations. The mast cell-145 forming potential was assessed via liquid culture as described previously. 23 Briefly, 146 sorted cells were cultured in medium with recombinant human (rh) IL-3 (10 ng/mL; 147 PeproTech, Rocky Hill, NJ) and rhIL-6 (10 ng/mL; PeproTech). In some experiments, 148 the medium was changed on day 5, and the cells were subsequently cultured with 149 rhIL-6 (10 ng/mL) and SCF (100 ng/mL, r-metHuSCF; Swedish Orphan Biovitrum, 150
Stockholm, Sweden), as indicated in the figure legends. Enzyme cytochemical 151 staining of trypsin-like activity was used to assess tryptase expression. 24 Laboratories). A mutation assay was designed based on a previously published 164 method 11 using Primer3 (v.0.4.0) which specifically detected KIT D816V using the 165 forward primer 5'-AGAGACTTGGCAGCCAGAAA-3'; a reverse primer matching 166 the mutation at the 3' position, 5'-167 TTAACCACATAATTAGAATCATTCTTGATGA-3'; and the probe 5'-FAM-168 TCCTCCTTACTCATGGTCGGATCACA-BHQ1-3'. A control assay was designed 169 to target a flanking exon and intron eight in GAPDH using the forward primer 5'-170 CTGACTTCAACAGCGACACC-3'; the reverse primer 5'-171 AGAGTTGTCAGGGCCCTTTT-3'; and the probe 5'-HEX-172 TCAAGCTCATTTCCTGGTATGTG-BHQ1-3' (all primers came from TAG 173
Copenhagen, Denmark). The control and mutation assays were tested and optimized 174 using the cell lines ROSA KIT WT and HMC-1.2. The primer concentrations, optimized 175 for single cells, were as follows; control assay 150 nM forward/reverse primers, 100 176 nM probe; mutation assay 100 nM forward/reverse primers, 67 nM probe. Each plate, 177 containing 86 CD34 + cells, 5 mature mast cells, 3 empty wells, and 2 wells with bulk 178 CD34 + cells following sorting, was subjected to the multiplex qPCR assay. Cells were 179 excluded from analysis when amplification failed in the control assay, or when 180 amplification of the control assay resulted in a CT value higher than 40. In the 181 mutation assay, cells were regarded as unmutated when there was no amplification or 182 when the CT value was higher than 45. Outliers from each plate were then detected 183 using the ROUT outlier test in Prism software and removed from further analyses 184 ( Figure S5B ). Plates and cells that passed the quality control procedure were linked 185 with the index data and gated similarly to the whole sample for analysis. To assess the composition of the hematopoietic cells in the bone marrow of SM 202 patients, we designed a multicolor flow cytometry panel that identifies ten distinct 203 HSPC subtypes and mature mast cells (Table 1 ; Figures 1A-B ). Colony formation 204 assays confirmed the validity of the GMP, CMP, and MEP gating strategies in SM 205 subjects ( Figure S1A -C). The flow cytometry data provided a specific HSPC profile 206 for 34 bone marrow samples: 9 control, 19 ISM and 6 AdvSM (Table S1; Figure 1C ). 207
The percentages of HSPCs in SM samples did not significantly differ from those in 208 control samples ( Figures 1D and S2A ). In addition, the ISM and AdvSM samples 209 exhibited percentages of total CD34 + cells similar to the control samples ( Figure  210 10 S2B). Thus, the overall hematopoiesis profile did not differ between the control and 211 SM subjects. 212
213
The bone marrow CMP FcεRI+ fraction presents an enhanced mast cell-forming 214 potential 215
Mast cell progenitors circulate in the blood as Lin -CD34 hi CD117 int/hi FcεRI + cells. 33 216
These cells express CD123 and lack CD45RA, 23,33 overlaying the CMP FcεRI+ gate in 217 bone marrow ( Figure S3A ). We therefore analyzed the mast cell-forming potential of 218 the bone marrow CMP FcεRI+ fraction by culturing the cells with IL-3 and IL-6. Flow 219 cytometry analysis revealed that the CMP FcεRI+ cultures gave rise to a higher 220 frequency of CD117 hi FcεRI + mast cells than the CMPs FcεRIcells ( Table S2 ). Taken together, the results indicate 246 that SM bone marrow samples contain more mast cells than control samples and these 247 mast cells express the aberrant marker CD45RA. 248 249
Single-cell index sorting reveals the KIT D816V mutation in early HSPCs in systemic 250

mastocytosis patients 251
The cellular origin of the KIT D816V mutation in SM has not been established, and 252 the relative abundance of this mutation in different CD34 + HSPC populations and 253 mast cells has not been determined. We therefore developed a single-cell method to 254 trace the KIT D816V mutation using two cell lines: HMC-1.2 cells carrying the 255 mutation and ROSA cells carrying wild-type KIT. The cells were labeled with two 256 different fluorochrome-labeled antibodies, mixed, and randomly FACS sorted with 257 the index sort function. A multiplex qPCR assay was used to detect an irrelevant gene, 258 for quality control purposes, and the KIT D816V mutation ( Figure S5A-B ). Among all 259 single cells, more than 96% passed the quality control procedure ( Figure S5C ). 260
Linking the results with the index data revealed that the mutation assay was negative 261 for the wild-type ROSA cells. The assay detected the mutation in 98.1% of all HMC-262 1.2 cells. Thus, the assay did not detect false positive cells in the mutation assay and 263 only a few false negatives, demonstrating the high sensitivity and specificity of the 264 method ( Figure S5D ). 265
266
The high success rate with cell lines allowed us to use the assay for HSPCs and 267 mature mast cells from patient samples. Single cells from 12 samples (6 ISM and 6 268 AdvSM) were analyzed for mutation assessment. Specifically, CD34 + HSPCs were 269 index sorted from ten patients, whereas specific HSPC subsets were sorted from two 270 patients. At the time of SM diagnosis, the presence of the KIT D816V mutation was 271 confirmed in either peripheral blood or bone marrow (Table S1 ). We analyzed 40-194 272 single mast cells and 351-1583 single CD34 + cells from each bone marrow sample, 273 providing mutation data for 12,859 single cells in total ( Figure 5A ; Table S3 ). All SM 274 samples carried the KIT D816V mutation in the mast cell compartment at a high 275 frequency in ISM (mean, 80.9%) and AdvSM (mean, 93.2%) ( Figure 5B ). The 276 percentage of mutated mast cells was correlated with the total percentage of mast cells 277 in the sample and with the serum tryptase levels ( Figure 6A-B ; Table S2 ). The 278 mutation rate in CD34 + HSPCs was less than 2.7% in all samples ( Figure 5C ), except 279 for one advanced SM sample with a high mutation burden of 37.0% (Table S4) . 280
Nevertheless, the percentage of mutated CD34 + HSPCs was correlated with serum 281 tryptase levels ( Figure 6C ; Table S2 ). 282
283
Coupling the index data with the mutation analysis of 10 bone marrow samples 284 revealed that the KIT D816V mutation appeared throughout the hematopoietic 285 13 landscape ( Figure 5D ; Table S3 -4). Specifically, different HSPCs presented similar 286 mutation rates in all samples when the median percentage of mutation was compared 287 between different HSPCs ( Figure 5E ). Overall, the method of index sorting provided a 288 representative set of single cells from the whole-bone-marrow aspirates ( Figure S6A ). 289
However, the CMP FcεRI+ population with an enriched mast cell potential was rare. To 290 determine the mutation frequency in the CMP FcεRI+ fraction, we selectively sorted 86 291 and 278 single CMPs FcεRI+ from 2 SM samples. One patient exhibited less than 2% 292 mutated CMPs FcεRI+ , HSCs and GMPs, whereas the fraction of mutated mast cells was 293 98.9% ( Figure 5F ; Table S4 ). The second patient presented 95.7% mutated 294 CMPs FcεRI+ and 96.4 % mutated mast cells. ( Figure 5G ; Table S4 ). Peripheral blood 295
MCPs (CD14 -CD34 + CD117 + FcεRI + ) showed mutation rates comparable to that of 296 bone marrow CMPs FcεRI+ in one patient ( Figure S6B The KIT D816V mutation causes receptor autoactivation, which signals survival, 310 proliferation, and differentiation, likely explaining the competitive growth advantage 311 of the aberrant mast cell clone and the high frequency of mutated mast cells. 312
However, the frequency of mutated HSPCs was low in most patients. This 313 observation is consistent with the overall normal HSPC composition of SM patients. 314
There are two main potential explanations for the low D816V mutation burden 315 observed in HSPCs and its accumulation in mast cells: HSPCs rapidly differentiate 316 into mast cells when the mutation occurs, or mutated HSPCs do not present a strong 317 growth advantage over non-mutated HSPCs. In fact, we have previously shown that 318
KIT signaling is dispensable for mast cell progenitor development, and that other 319 stimuli can induce cell proliferation. 23 However, the aberrant progenitor clone may in 320 some cases proliferate to reach a high frequency, as demonstrated in two patients with 321 advanced SM who presented more than 20% mutated cells in the HSC fraction. 322
Advanced forms of SM have previously been associated with detection of the KIT 323 mutation in bulk-sorted CD34 + progenitors and various mature cell lineages, whereas 324 in indolent disease, the mutation is mainly restricted to mast cells. 13 325 326 It is of particular interest to study the mutation burden in progenitors with mast cell-327 forming potential. We have previously reported that CD34 + CD117 int/hi FcεRI + cells in 328 peripheral blood are committed or nearly committed MCPs. 33 Considering the CD34 + 329 CD117 + FcεRI + phenotype of CMPs FcεRI+ cells, these cells might be expected to 330 present a similar mast cell-forming capacity as to blood MCPs. In the current study, 331
we showed that CMPs FcεRI+ gave rise to a higher frequency of mast cells than 332
CMPs FcεRIand GMPs. However, the mast cell frequency in cultured CMPs FcεRI+ was 333 less than 10% and a substantial fraction were found to be CD117 -/lo FcεRI + cells after 334 culture, consistent with a basophil-like phenotype. Thus, CMPs FcεRI+ CD45RA is present on aberrant mast cells in SM, but at what stage during mast cell 360 differentiation is the marker upregulated? CMPs FcεRI+ , which lack CD45RA, present 361 mast cell-forming potential in SM patients. In contrast, we show that cells in the 362 classic CD45RA + GMP gate lack mast cell potential in SM patients. An alternative 363 explanation is that the mast cell progenitors in SM fall into the immature CD38gate. 364
In fact, examples of rare mutated CD117 int/hi FcεRI int/hi cells in the CD45RA + LMPP 365 gate were seen ( Figure S6C ). It is also tempting to speculate that CD45RA is 366 upregulated once aberrant mast cells are mature. 367
368
The CD34 + HSPC population is highly heterogeneous and a single-cell resolution is 369 therefore necessary to delineate the cellular distribution of the mutation. Here, we 370 Table S2 . Linear regression was calculated based on log-transformed data: in 584 panel A, n = 25, and in panels B and C, n = 23. The percentage of BMMC infiltrate 585 26 was not determined for two patients, accounting for the difference in numbers 586 between panels. For analytical purposes, BMMC infiltrate presented as <1% or <5% 587
in Table S1 were set at 1% and 5% respectively. Table S2 . Linear regression was 606 calculated based on log-transformed data in panels A-C, n = 12 and D, n = 10. 2  4  5  24  26  29  37  38  113  7  8  9  10  11  13  104  105  19  20  21  22  23  25  28  32  33  36  39  6  14  16  17  18 
